Roche's I/O 2.0 dreams take a hit as TIG­IT in­hibitor fails PhI­II

In a dis­ap­point­ing set­back for one of the bright­est can­di­dates in the next-gen check­point race, tiragolum­ab — Roche’s “break­through” TIG­IT drug — has failed a Phase III tri­al.

The can­di­date failed to meet the co-pri­ma­ry end­point of pro­gres­sion-free sur­vival among a group of pa­tients with ex­ten­sive-stage small cell lung can­cer (ES-SCLC), Roche dis­closed Wednes­day morn­ing. Over­all sur­vival, the oth­er co-pri­ma­ry end­point in the SKY­SCRAPER-02 study, was not met at the in­ter­im analy­sis and is “un­like­ly to reach sta­tis­ti­cal sig­nif­i­cance at the planned fi­nal analy­sis,” the com­pa­ny added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER